Time to grade 2 or higher bleeding
Characteristic . | N . | % censored . | Hazard ratio . | 95% CI . | P . |
---|---|---|---|---|---|
Randomized treatment group | .77 (2 df) | ||||
LD | 247 | 51.0 | 1.00 | 0.77-1.30 | .99 |
MD | 251 | 54.2 | Referent category | ||
HD | 280 | 47.5 | 1.08 | 0.84-1.39 | .54 |
Platelet source | .44 | ||||
Apheresis | 552 | 54.5 | Referent category | ||
WBP | 220 | 53.2 | 1.15 | 0.81-1.65 | .44 |
ABO matching status | .33 (2 df) | ||||
ABO-identical | 467 | 64.2 | Referent category | ||
Minor mismatch | 75 | 76.0 | 0.85 | 0.52-1.40 | .52 |
Major mismatch | 198 | 75.8 | 0.78 | 0.56-1.09 | .15 |
Storage duration, d | .87 (3 df) | ||||
0-2 | 48 | 83.3 | 0.86 | 0.39-1.87 | .70 |
3 | 158 | 79.8 | Referent category | ||
4 | 223 | 81.2 | 1.03 | 0.64-1.64 | .91 |
5 | 221 | 77.8 | 1.13 | 0.72-1.79 | .59 |
Characteristic . | N . | % censored . | Hazard ratio . | 95% CI . | P . |
---|---|---|---|---|---|
Randomized treatment group | .77 (2 df) | ||||
LD | 247 | 51.0 | 1.00 | 0.77-1.30 | .99 |
MD | 251 | 54.2 | Referent category | ||
HD | 280 | 47.5 | 1.08 | 0.84-1.39 | .54 |
Platelet source | .44 | ||||
Apheresis | 552 | 54.5 | Referent category | ||
WBP | 220 | 53.2 | 1.15 | 0.81-1.65 | .44 |
ABO matching status | .33 (2 df) | ||||
ABO-identical | 467 | 64.2 | Referent category | ||
Minor mismatch | 75 | 76.0 | 0.85 | 0.52-1.40 | .52 |
Major mismatch | 198 | 75.8 | 0.78 | 0.56-1.09 | .15 |
Storage duration, d | .87 (3 df) | ||||
0-2 | 48 | 83.3 | 0.86 | 0.39-1.87 | .70 |
3 | 158 | 79.8 | Referent category | ||
4 | 223 | 81.2 | 1.03 | 0.64-1.64 | .91 |
5 | 221 | 77.8 | 1.13 | 0.72-1.79 | .59 |
Adjusted frailty models of days from first platelet transfusion to ≥ grade 2 bleeding. Hazard ratios > 1.00 indicate higher risk of bleeding in patients receiving platelets with the specified characteristic compared with patients receiving platelets with the reference characteristic. Each model includes one platelet characteristic (randomized dose assignment, source, matching status, or storage duration) and is also adjusted for patient sex, patient age group, patient treatment category, and site (with site treated as a random effect). Data on time to bleeding were censored if any of the following occurred before the patient experienced grade 2 or higher bleeding: a transfusion that differed from the patient's first transfusion in the characteristic being analyzed or had missing data on that characteristic; a day with missing data on whether grade 2 or higher bleeding had occurred; or end of study.
N indicates number of evaluable patients; LD, low dose; MD, medium dose; HD, high dose; and WBP, whole blood platelet pools.